DWTX · Dogwood Therapeutics, Inc.

Dogwood Therapeutics reported its first quarter 2026 financial results, highlighting a net loss attributable to common stockholders of $5.0 million, or $0.15 per share, compared to a net loss of $12.2 million, or $8.45 per share, in the same period last year. The significant reduction in net loss per share was primarily due to a substantial increase in weighted average shares outstanding to 33.5 million from 1.4 million, reflecting the January 2026 financing. Operating expenses rose to $5.1 million from $4.4 million, driven by higher R&D costs ($2.7 million vs. $2.4 million) and G&A expenses ($2.4 million vs. $2.0 million). The company ended the quarter with $13.2 million in cash, providing runway into Q4 2026. Key pipeline milestones include the Halneuron Phase 2b CINP trial, which has enrolled 164 patients with top-line results expected in fall 2026, and SP16, which received FDA IND approval for a Phase 1b CIPPN trial fully funded by the National Cancer Institute. Management expressed confidence in the operational progress, citing the strong start to 2026 and the execution of a global development license for legacy antiviral assets. The financing of up to $26.9 million, with $12.5 million received, supports Halneuron development through Phase 2b. The company also noted that any payments from the development partnership may trigger distributions to CVR holders.